Compass Therapeutics Investor Presentation Deck

Phase 2 CTX-009 Combination Study - Patient Demographics Age Median (years) Gender, n(%) Male Female ECOG performance status, n(%) 0 1 COMPASS THERAPEUTICS 24 Total Patients 61.5 14 (58%) 10 (42%) 13 (54%) 11 (46%) Prior systemic therapies, n(%) 1 2 Prior Gem/Cis regimen BTC subtype, n (%) Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Gallbladder cancer Ampullary cancer 24 Total Patients 11 (46%) 13 (54%) 23 (96%) 9 (38%) 3 (13%) 7 (29%) 5 (21%) 16

View entire presentation